Canadian Agency for Drugs and Technologies in Health. (2017). Patient group input submissions AbobotulinumtoxinA (Dysport therapeutic ULS) for the symptomatic treatment of focal spasticity affection the upper limbs in adults. Canadian Agency for Drugs and Technologies in Health.
Chicago Style (17th ed.) CitationCanadian Agency for Drugs and Technologies in Health. Patient Group Input Submissions AbobotulinumtoxinA (Dysport Therapeutic ULS) for the Symptomatic Treatment of Focal Spasticity Affection the Upper Limbs in Adults. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health, 2017.
MLA (9th ed.) CitationCanadian Agency for Drugs and Technologies in Health. Patient Group Input Submissions AbobotulinumtoxinA (Dysport Therapeutic ULS) for the Symptomatic Treatment of Focal Spasticity Affection the Upper Limbs in Adults. Canadian Agency for Drugs and Technologies in Health, 2017.